The company has now completed its internal investigation into certain intra-company transactions that impacted its previously reported non-operating foreign exchange gains and losses as it relates to the financial statement impacts. Delivering innovative surgical products that help you operate with confidence, precision and speed. ... but we don't expect to see that in Q3 and Q4 to the same extent. January 31, 2019. Adjusted earnings per diluted share increased 37% in the quarter, driven by solid operational performance and an ongoing benefit from the company’s business transformation efforts. For the quarter and year ended December 31, 2019, operational sales growth excludes the impact of foreign exchange and generic competition for U.S. cyclophosphamide. Baxter further indicated that the Company is investigating misstatements in previously reported non-operating income. Additionally, intangible asset amortization is excluded as a special item to facilitate an evaluation of current and past operating performance and is consistent with how management and the company’s Board of Directors assess performance. An ensemble family drama based on the bestselling novels from Karen Kingsbury, that follows Elizabeth and John Baxter, and their adult children, as they navigate life's highs and lows, both with and without God. Was named to Newsweek’s list of America’s Most Responsible Companies. Our forward-looking leadership team is a driving force in ensuring we meet the needs of all our stakeholders – every day and everywhere. Baxter International Inc. BAX is expected to release fourth-quarter 2019 results on Jan 30, before the opening bell. Our forward-looking leadership team is a driving force in ensuring we meet the needs of all our stakeholders – every day and everywhere. All three of Baxter’s geographic segments also contributed positively to growth for the year. Baxter International Inc. Fourth-Quarter 2018 Earnings. We are committed to doing business the right way, ensuring that we champion our employees, our communities, our customers and patients, and our environment in everything we do. In 2019, Baxter generated $2.1 billion in operating cash flow, driven by improved operational performance and the continuing impact of programs focused on improving the company’s working capital. For more than 85-years, we have worked at the intersection of saving and sustaining lives. Sales in the U.S. totaled $4.8 billion, increasing 2% on a reported basis and 3% on an operational basis. Our more than 85-year heritage gives us distinct perspective on the needs of patients and caregivers. Providing innovative therapies and technologies to help you treat patients with life-threatening illnesses in the ICU. Baxter annual revenue for 2018 was $11.099B, a 4.87% increase from 2017. 17, 2020 Baxter International (BAX) Presents At Raymond James Institutional Investors Conference - Slideshow BAXTER INTERNATIONAL INC. Intangible asset amortization is excluded as a special item to facilitate an evaluation of future and past operating performance and is consistent with how management forecasts future performance. [Operator Instructions] Chronic kidney disease (CKD) is an ongoing journey. CONSIDER DESIGN-BUILD. For full-year 2019: Baxter expects sales growth of 0 to 1 percent on a reported basis, 2 to 3 percent on a constant currency basis and 3 to 4 percent on an operational basis. Since the emergence of COVID-19 (coronavirus), Baxter has implemented a detailed action plan, which includes taking proactive measures to protect employee workplace safety, providing aid to healthcare providers and those affected by the pandemic, and maintaining global supply of its products. For more than 85 years, we’ve been focused on saving and sustaining lives and elevating patient care. March 17, 2020 07:30 AM CST. Mar. "Our investigation of this matter as it relates to its financial impacts is now complete," said Mr. Almeida. Baxter also filed its 3Q Form 10-Q, which included restated unaudited financial statements for the quarterly and year-to-date periods ended September 30, 2018. All Forms filed with the U.S. Securities and Exchange Commission sorted by year. Image source: The Motley Fool. View this Presentation (PDF) Raymond James 41st Annual Institutional Investors Conference. Baxter International Inc. Q1 2019 Earnings Conference Apr 25, 2019 • 08:30 am ET . Baxter (BAX) delivered earnings and revenue surprises of 6.85% and 1.45%, respectively, for the quarter ended December 2018. Consumer demand, collaboration with dealers, increased U.S. production and improved inventory levels propel strong fourth quarter. GlobalData provides unique data, expert analysis & innovative solutions to companies in the world’s largest industries Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the first quarter of 2019 and increased its full-year 2019 earnings outlook. Patients’ journeys inspire our work and drive our commitment. Google has many special features to help you find exactly what you're looking for. Watch Queue Queue Operational sales for 2019 adjust for the impact of foreign exchange and generic competition for U.S. cyclophosphamide. For the fourth quarter, the net loss from continuing operations attributable to Baxter was $23 million, or $0.05 per diluted share, on a U.S. GAAP (Generally Accepted Accounting Principles) basis. Do the numbers hold clues to what lies ahead for the stock? Selected Financial Data. We are committed to attracting, motivating and retaining an inclusive and diverse workforce. Baxter International (BAX) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.73 per share. "Our sales and earnings performance in 2019 demonstrate the momentum and underlying strength of our ongoing transformation," said José (Joe) E. Almeida, chairman, president and chief executive officer. Baxter revenue for the twelve months ending September 30, 2020 was $11.531B, a 3.49% increase year-over-year. 7 Metric Q4 2018 Dan Aldridge - Vice President, Investor Relations. Baxter International Inc. 2019 Q4 - Results - Earnings Call Presentation Mar. Most recently the company: In addition, Baxter continues to be recognized for its commitment to corporate social responsibility and workplace excellence. BMW Light Truck sales increase 9.6% in Q4 2020 vs Q4 2019; Full BMW X model line-up accounts for 60% of 2020 sales. — Worldwide sales grew 8% on a constant currency basis and 9% on an operational basis. Change your search criteria: Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced its complete financial results for the fourth quarter and full year ended December 31, 2019. Baxter's 2019 worldwide sales totaled approximately $11.4 billion, an increase of 2% on a reported basis and 5% on both a constant currency and operational basis compared to 2018. Q4 2020 sales greatly exceed expectations, down only 2.0% in a challenging year. Listen to "Q4 2019 Baxter International Inc Earnings Call". Baxter International (BAX) Presents At Raymond James Institutional Investors Conference - Slideshow. "We are driving growth across our global businesses and regions, fueled by innovation and commercial execution that position us for sustained success. Baxter International Inc. BAX reported fourth-quarter 2018 adjusted earnings of 78 cents per share, which surpassed the Zacks Consensus Estimate of. Future events or new information may result in different actual results. Among highlights of the past year, the company: Baxter's progress continues into 2020, as reflected in additional highlights to open the year. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. Baxter International Inc. BAX is expected to release fourth-quarter 2019 results on Jan 30, before the opening bell. $1.3 billion. For more information about the restatement, including the impacts on the company’s financial statements, see Baxter’s Form 10-K and the 3Q Form 10-Q. While to date Baxter has experienced limited financial impact from COVID-19, given the rapid and evolving nature of the virus, the company is not in a position to provide an estimate of any potential negative impact on its full-year financial results. Joe Almeida shares his outlook on a range of topics. Baxter (NYSE: BAX) Q4 2018 Earnings Conference Call Jan. 31, 2019 8:30 a.m. Baxter expects operating margin to be between 15.2% and 15.9% on a reported basis and between 18.5% and 19% on an adjusted basis. Committed to helping you meet the evolving challenges and opportunities in patient care. 1See www.baxter.com for information regarding non- GAAP financial metrics used in this presentation, including constant currency and operational sal es, adjusted gross margin, adjusted operating margin, adjusted diluted EPS, free cash flow, adjusted SG&A expense, adjusted R&D e xpense, and adjusted operating expense. In addition, over the last couple of years Baxter has executed several actions to enhance and diversify its global supply chain network. International: (225) 239-4663 This measure provides information on the change in net sales growth rates assuming that foreign exchange rates remain constant and excludes the impact of sales related to the company's Seprafilm acquisition. As a result of these filings, Baxter is now current in its reporting obligations with the SEC. Download, follow and add "Baxter International Inc." earnings calls to your podcast at EarningsCast. Baxter International Inc. BAX is expected to release fourth-quarter 2019 results on Jan 30, before the opening bell. We lead today by putting those insights to work to deliver new, better healthcare solutions and access to care in the communities where we live and work. Consistent with the company’s focus on corporate citizenship and its Mission to Save and Sustain Lives, Baxter colleagues have been providing frontline support to healthcare providers combating the spread of COVID-19. Certain of those items represent estimates based on information reasonably available at the time of the press release. Scored 100% on the Human Rights Campaign Corporate Equality Index for the fifth consecutive year. Do the numbers hold clues to what lies ahead for the stock? Our portfolio of acute, nutritional, renal, hospital and surgical care products helps advance healthcare around the world. Baxter annual revenue for 2019 was $11.362B, a 2.37% increase from 2018. Helping you reach a healthy life, full of possibility. Baxter International Inc. 2019 Q4 - Results - Earnings Call Presentation. "The relevant foreign exchange gains and losses were non-operational in nature, and our core operational performance across this period continues to demonstrate the strength and trajectory of our ongoing transformation, fueled by revitalized innovation, increased efficiency and the dedication of our 50,000 employees worldwide.". Acute and chronic nutritional care for your patients who are unable to get adequate nutrients orally or enterally. Domestic: (844) 886-1929 — Sales in the US rose 10% to approx. Design-Build offers … Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced certain preliminary operating results for the quarter ended September 30, 2019. In 2019, Baxter achieved many milestones in pursuit of its Mission for patients and emphasis on accelerating profitable ... Q4 2019. Please see the schedules accompanying this press release for reconciliations of non-GAAP measures to the most closely related U.S. GAAP measures. A webcast of Baxter's fourth-quarter 2019 conference call for investors can be accessed live from a link on the company’s website at www.baxter.com beginning at 7:30 a.m. CST on March 17, 2020. We are committed to doing business the right way, ensuring that we champion our employees, our communities, our customers and patients, and our environment in everything we do. Information regarding Baxter’s recent announcements, upcoming & past events, and other useful resources for investors. 2 See links to original press releases for additional product information, including Boxed Warning for Clinolipid. Baxter annual revenue for 2018 was $11.099B, a 4.87% increase from 2017. These results include special items totaling $716 million after-tax, primarily due to a noncash pension settlement charge, business optimization expenses, and intangible asset amortization, partially offset by benefits related to global tax reform and insurance recoveries. Good morning, ladies and gentlemen and welcome to Baxter International's Second Quarter 2019 Earnings Conference Call. Events & News. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: developments in connection with the investigation related to foreign exchange gains and losses; demand for and market acceptance of risks for new and existing products; product development risks; product quality or patient safety concerns; continuity, availability and pricing of acceptable raw materials and component supply; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of a natural disaster, public health crises and epidemics/pandemics, regulatory actions or otherwise); breaches or failures of the company’s information technology systems or products, including by cyberattack, unauthorized access or theft; the adequacy of the company’s cash flows from operations and other sources of liquidity to meet its ongoing cash obligations and fund its investment program; loss of key employees or inability to identify and recruit new employees; future actions of regulatory bodies and other governmental authorities, including the FDA, the Department of Justice, the SEC, the New York Attorney General and foreign regulatory agencies, including the continued delay in lifting the warning letter at our Ahmedabad facility or proceedings related to the investigation related to foreign exchange gains and losses; the outcome of pending or future litigation, including the opioid litigation and litigation related to our internal investigation of foreign exchange gains and losses; the impacts of the material weakness identified as a result of the internal investigation and our remediation efforts, including the risk that we may experience additional material weaknesses or other deficiencies; proposed regulatory changes of the U.S. Department of Health and Human Services in kidney health policy and reimbursement, which may substantially change the U.S. end stage renal disease market and demand for our peritoneal dialysis products, necessitating significant multi-year capital expenditures, which are difficult to estimate in advance; failures with respect to compliance programs; accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits (including the acquisitions of Cheetah Medical and Seprafilm Adhesion Barrier from Sanofi); future actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; fluctuations in foreign exchange and interest rates; the ability to enforce owned or in-licensed patents or the prevention or restriction of the manufacture, sale or use of products or technology affected by patents of third parties; the impact of global economic conditions (including potential trade wars) and public health crises and epidemics, such as the novel strain of coronavirus that recently originated in China (COVID-19), on us and our customers and suppliers, including foreign governments in countries in which we operate; global, trade and tax policies; any change in laws concerning the taxation of income (including current or future tax reform), including income earned outside the United States and potential taxes associated with the Base Erosion and Anti-Abuse Tax; actions taken by tax authorities in connection with ongoing tax audits; and other risks identified in Baxter’s most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter’s website.